Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India

Immune checkpoint inhibitor (PD-L1) therapy of advanced non-small-cell lung cancer (NSCLC) has variable outcomes. Tumor subtypes based on PD-L1 expression, histopathology, mutation burden is required for patient stratification and formulation of treatment guidelines. Lung cancers (n=57) diagnosed at...

Celý popis

Podrobná bibliografia

Vydané v:	Monaldi archives for chest disease Ročník 93; číslo 4
Hlavní autori:	Kulshrestha, Ritu, Saxena, Himanshi, Kumar, Raj, Spalgius, Sonam, Mrigpuri, Parul, Goel, Nitin, Menon, Balakrishnan, Rani, Meenu, Mahor, Pawan, Bhutani, Ishita
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Italy PAGEPress Publications 01.02.2023
Predmet:	Subtyping-lung cancer, PD-L1, coexisting EGFR/KRAS mutations, tumour histopathology, North India
ISSN:	1122-0643, 2532-5264, 2532-5264
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!